Live Earnings Conference Call: Exact Sciences will host a live Q1 2025 earnings call on May 1, 2025 at 5:00PM ET. Follow this link to get details and listen to Exact Sciences' Q1 2025 earnings call when it goes live. Get details. Exact Sciences (EXAS) Competitors $45.64 +0.85 (+1.90%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. ALNY, BIIB, UTHR, BMRN, INCY, EXEL, NBIX, RGEN, HALO, and MDGLShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Exelixis Neurocrine Biosciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Exact Sciences (NASDAQ:EXAS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Do institutionals & insiders have more ownership in EXAS or ALNY? 88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, EXAS or ALNY? Exact Sciences has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Do analysts recommend EXAS or ALNY? Exact Sciences presently has a consensus price target of $69.25, indicating a potential upside of 51.73%. Alnylam Pharmaceuticals has a consensus price target of $315.58, indicating a potential upside of 19.88%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Exact Sciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Does the media refer more to EXAS or ALNY? In the previous week, Exact Sciences and Exact Sciences both had 25 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 1.02 beat Exact Sciences' score of 0.91 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exact Sciences 12 Very Positive mention(s) 6 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 17 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Is EXAS or ALNY more profitable? Alnylam Pharmaceuticals has a net margin of -12.37% compared to Exact Sciences' net margin of -37.29%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-37.29% -5.29% -2.45% Alnylam Pharmaceuticals -12.37%N/A -6.83% Which has higher earnings and valuation, EXAS or ALNY? Exact Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.76B3.07-$204.15M-$5.57-8.19Alnylam Pharmaceuticals$2.25B15.23-$278.16M-$2.17-121.31 Does the MarketBeat Community prefer EXAS or ALNY? Alnylam Pharmaceuticals received 173 more outperform votes than Exact Sciences when rated by MarketBeat users. Likewise, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 73.14% of users gave Exact Sciences an outperform vote. CompanyUnderperformOutperformExact SciencesOutperform Votes99173.14% Underperform Votes36426.86% Alnylam PharmaceuticalsOutperform Votes116476.28% Underperform Votes36223.72% SummaryAlnylam Pharmaceuticals beats Exact Sciences on 10 of the 18 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.48B$2.88B$5.57B$7.83BDividend YieldN/A31.29%5.11%4.22%P/E Ratio-8.1913.2822.4418.48Price / Sales3.07188.21394.10103.91Price / Cash8.7957.5638.1834.62Price / Book3.534.676.774.25Net Income-$204.15M-$22.21M$3.22B$248.23M7 Day Performance3.52%0.36%3.25%3.29%1 Month Performance4.54%0.16%0.01%2.42%1 Year Performance-23.10%14.23%18.00%5.54% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.3999 of 5 stars$45.64+1.9%$69.25+51.7%-23.1%$8.48B$2.76B-8.196,400Positive NewsALNYAlnylam Pharmaceuticals4.3115 of 5 stars$254.85+1.3%$315.58+23.8%+82.9%$33.15B$2.25B-117.442,000Analyst DowngradePositive NewsBIIBBiogen4.6894 of 5 stars$119.12+0.2%$203.07+70.5%-43.6%$17.44B$9.68B10.658,720Analyst DowngradeAnalyst RevisionUTHRUnited Therapeutics4.9052 of 5 stars$297.04+1.9%$390.17+31.4%+29.3%$13.34B$2.88B13.05980Earnings ReportAnalyst RevisionNews CoveragePositive NewsGap UpBMRNBioMarin Pharmaceutical4.9208 of 5 stars$62.98-0.5%$93.14+47.9%-21.1%$12.02B$2.85B28.633,080Positive NewsINCYIncyte4.7048 of 5 stars$59.52+0.6%$74.69+25.5%+20.4%$11.52B$4.24B220.452,320Earnings ReportAnalyst ForecastEXELExelixis4.0788 of 5 stars$38.44+2.7%$37.59-2.2%+66.9%$10.59B$2.17B21.721,220Short Interest ↑Analyst RevisionPositive NewsNBIXNeurocrine Biosciences4.8613 of 5 stars$106.46-0.3%$160.90+51.1%-21.7%$10.53B$2.36B32.361,200Upcoming EarningsAnalyst ForecastAnalyst RevisionRGENRepligen4.8903 of 5 stars$143.63-0.8%$176.82+23.1%-16.0%$8.06B$634.44M-281.632,020Earnings ReportAnalyst UpgradeNews CoverageHALOHalozyme Therapeutics4.0044 of 5 stars$60.57+0.1%$62.89+3.8%+61.2%$7.48B$1.02B17.66390Upcoming EarningsInsider TradeAnalyst RevisionMDGLMadrigal Pharmaceuticals3.7505 of 5 stars$331.29+1.4%$409.00+23.5%+63.7%$7.31B$180.13M-13.2190News CoveragePositive NewsGap Down Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives BioMarin Pharmaceutical Alternatives Incyte Alternatives Exelixis Alternatives Neurocrine Biosciences Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXAS Stock Free EXAS Stock Alerts